<DOC>
	<DOCNO>NCT00771823</DOCNO>
	<brief_summary>A placebo control study impact insulin sensitivity lipid profile maraviroc 300 mg twice daily HIV negative male volunteer .</brief_summary>
	<brief_title>Maraviroc 300 mg Twice Daily HIV Negative Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects must document negative HIV serology ELISA P24 antigen Subjects must clinically well male age 18 60 year . Fasting blood glucose , total cholesterol triglyceride within normal limit Hepatic transaminase ( AST ALT ) ≤ 3 × upper limit normal ( ULN ) Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm3 ; platelet ≥ 50,000/mm3 ; hemoglobin ≥ 8.0 g/dL ) Serum amylase ≤ 1.5 × ULN Sexually active male must use condom course study Life expectancy ≥ 1 year Willing able provide inform consent Subjects waist hip ratio &gt; 0.97 BMI &gt; 28 kg/m2 exclude Acute chronic hepatitis B infection ( determine positive hepatitis B surface antigen result screen visit ) Acute chronic hepatitis C infection ( determine positive hepatitis C antibody result screen visit ) Other metabolic syndrome disease process opinion investigator likely cause mark disturbance glucose lipid homeostasis include hypertension . Receiving ongoing therapy following : Metabolically active medication Any lipidlowering medication Hormonal agent ( oestrogen androgen ) Glucocorticoids Betablockers Thiazide diuretic Thyroid preparation Psychotropic agent Anabolic steroid Megestrol acetate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>